BRPI0414633A - composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit - Google Patents

composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit

Info

Publication number
BRPI0414633A
BRPI0414633A BRPI0414633-6A BRPI0414633A BRPI0414633A BR PI0414633 A BRPI0414633 A BR PI0414633A BR PI0414633 A BRPI0414633 A BR PI0414633A BR PI0414633 A BRPI0414633 A BR PI0414633A
Authority
BR
Brazil
Prior art keywords
compound
diagnostic composition
doagnosis
disease
condition
Prior art date
Application number
BRPI0414633-6A
Other languages
English (en)
Inventor
Peter Dorff
John Gordon
John Richard Heys
Richard A Keith
Dennis J Mccarthy
Eifion Phillips
Mark A Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0414633A publication Critical patent/BRPI0414633A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO, COMPOSIçãO DE DIAGNóSTICO, MéTODO PARA A DIAGNOSE DE DOENçAS OU CONDIçõES, E, KIT". Um composto radioativo tendo a fórmula (I) onde R¬ 1¬ e Ar são como definidos no relatório descritivo, sais farmaceuticamente aceitáveis destes, composições contendo tais compostos e os usos destes em diagnoses de condições em que o receptor nicotinico <244>~ 7~ está envolvido.
BRPI0414633-6A 2003-09-25 2004-09-24 composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit BRPI0414633A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50573103P 2003-09-25 2003-09-25
PCT/GB2004/004116 WO2005030778A1 (en) 2003-09-25 2004-09-24 Ligands

Publications (1)

Publication Number Publication Date
BRPI0414633A true BRPI0414633A (pt) 2006-11-07

Family

ID=34393060

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414633-6A BRPI0414633A (pt) 2003-09-25 2004-09-24 composto, composição de diagnóstico, método para a doagnose de doenças ou condições, e, kit

Country Status (14)

Country Link
US (1) US7982038B2 (pt)
EP (1) EP1668016A1 (pt)
JP (1) JP4792393B2 (pt)
KR (1) KR20060102328A (pt)
CN (1) CN1856497A (pt)
AU (2) AU2004276061A1 (pt)
BR (1) BRPI0414633A (pt)
CA (1) CA2538705A1 (pt)
IL (1) IL174218A0 (pt)
MX (1) MXPA06003196A (pt)
NO (1) NO20061819L (pt)
NZ (1) NZ546414A (pt)
WO (1) WO2005030778A1 (pt)
ZA (1) ZA200602445B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726189A (en) * 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
CA2482313A1 (en) 2002-04-18 2003-10-23 Astrazeneca Ab Heterocyclic compounds
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
AU2003283648A1 (en) * 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor

Also Published As

Publication number Publication date
IL174218A0 (en) 2006-08-01
JP2007506719A (ja) 2007-03-22
MXPA06003196A (es) 2006-06-23
AU2004276061A1 (en) 2005-04-07
CN1856497A (zh) 2006-11-01
EP1668016A1 (en) 2006-06-14
NO20061819L (no) 2006-06-26
CA2538705A1 (en) 2005-04-07
US20070172420A1 (en) 2007-07-26
NZ546414A (en) 2009-07-31
WO2005030778A1 (en) 2005-04-07
US7982038B2 (en) 2011-07-19
ZA200602445B (en) 2007-09-26
KR20060102328A (ko) 2006-09-27
JP4792393B2 (ja) 2011-10-12
AU2009200802A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
NO20054220L (no) Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
BR9808513A (pt) Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0213612A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BRPI0409592A (pt) compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
NO20045486L (no) Nye forbindelser og deres anvendelse
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
NO20052496L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20052633L (no) Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
BRPI0415746A (pt) derivados de amida
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
BRPI0512985A (pt) derivados de 3-carbamoil-2-piridona
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
BRPI0413695A (pt) derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
BRPI0111596B8 (pt) Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
NO20052825L (no) N-Arylsulfonyl-3-aminoalkoxyindoles
NO20040881L (no) Orale antidiabetes midler.
RU2413513C2 (ru) Антигельминтная композиция на основе соли четвертичного фосфония и замещенного динитробензофуроксана
NO20060718L (no) Substituerte tiofoner og deres anvendelse

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.